<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Surgical management of stress urinary incontinence in females: Pubovaginal sling procedures
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Surgical management of stress urinary incontinence in females: Pubovaginal sling procedures
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Surgical management of stress urinary incontinence in females: Pubovaginal sling procedures
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kimberly Kenton, MD, MS, FACOG, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Linda Brubaker, MD, FACOG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen Eckler, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H20186354">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical therapy for female stress urinary incontinence (SUI) includes pubovaginal slings, midurethral slings (with synthetic, polypropylene mesh), and Burch urethropexy  (
         <a class="graphic graphic_table graphicRef98504" href="/z/d/graphic/98504.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Although the midurethral sling using synthetic mesh is the most common procedure for treatment of SUI and the standard of care for most patients, some patients may not be candidates or may request surgical techniques that do not use synthetic mesh [
         <a href="#rid1">
          1,2
         </a>
         ]. This topic reviews pubovaginal (also known as suburethral or bladder neck) fascial sling procedures. In females undergoing surgical treatment, midurethral synthetic slings are generally preferred to pubovaginal fascial slings or Burch urethropexy [
         <a href="#rid3">
          3
         </a>
         ]. However, in those who decline or are not candidates for midurethral slings, pubovaginal autologous fascial slings remain an effective treatment for SUI.
        </p>
        <p>
         The evaluation, treatment and other surgical options for females with SUI are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6881.html" rel="external">
          "Female urinary incontinence: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8070.html" rel="external">
          "Female stress urinary incontinence: Choosing a primary surgical procedure"
         </a>
         .)
        </p>
        <p>
         In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.
        </p>
        <p class="headingAnchor" id="H20186612">
         <span class="h1">
          ANATOMIC LOCATION AND MATERIALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pubovaginal slings are placed at the level of the proximal urethra or bladder neck [
         <a href="#rid4">
          4
         </a>
         ]. The anterior rectus fascia (ie, pubovaginal sling) and pubic bone are the most common superior attachments for pubovaginal slings; however, the superior rectus fascia is preferred as most high-quality outcome data use the rectus fascia. In addition, bone anchors, used to attach the sling to the pubic bone, are associated with osteitis pubis and osteomyelitis [
         <a href="#rid5">
          5
         </a>
         ] and offer no improvement in outcomes.
        </p>
        <p>
         Sling materials include autografts (rectus fascia or fascia lata), allografts (fascia lata), xenografts (porcine dermis), and synthetic meshes (mersilene or expanded polytetrafluoroethylene). We use rectus fascia harvested from the patient (autologous) at the time of the sling surgery in most cases.
        </p>
        <p class="headingAnchor" id="H20186366">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The exact mechanism of continence created by the pubovaginal sling is unclear. It likely provides direct compression to the proximal urethra or provides a hammock against which the urethra is compressed during increases in abdominal pressure [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H415856625">
         <span class="h1">
          PATIENT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pubovaginal slings are reserved for women in whom midurethral slings are contraindicated, were unsuccessful, or who decline to have a synthetic material used for their sling. Two studies reported high SUI cure rates (70 to 90 percent) after pubovaginal sling procedures in women with prior unsuccessful synthetic midurethral sling insertions, particularly for women whose synthetic mesh was removed [
         <a href="#rid7">
          7,8
         </a>
         ]. However, in general, the midurethral sling is the standard of care for SUI, largely due to the decreases in morbidity and voiding dysfunction associated with midurethral slings as compared with pubovaginal slings [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8070.html" rel="external">
          "Female stress urinary incontinence: Choosing a primary surgical procedure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8070.html" rel="external">
          "Female stress urinary incontinence: Choosing a primary surgical procedure", section on 'Types of procedures'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20186378">
         <span class="h1">
          PREOPERATIVE EVALUATION AND CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         All women undergoing pubovaginal slings should
         <strong>
          at a minimum
         </strong>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Report bothersome SUI
         <strong>
          symptoms
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Demonstrate
         <strong>
          signs
         </strong>
         of SUI (ie, transurethral urine loss with increase in intraabdominal pressure prior to surgery)
        </p>
        <p>
        </p>
        <p>
         Office evaluation is adequate for women with predominant SUI symptoms planning to undergo a pubovaginal sling [
         <a href="#rid10">
          10,11
         </a>
         ]. If the urinalysis, cough stress test, and postvoid residual urine volume are consistent with uncomplicated SUI, then urodynamic testing is unnecessary. The additional information provided from urodynamic testing may be warranted in women who have persistent SUI symptoms after prior incontinence surgery, who have complicated urinary tract histories, who have urethral incompetence, or who have symptoms of mixed urinary incontinence. The preoperative evaluation of women undergoing incontinence surgery is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8088.html" rel="external">
          "Surgical management of stress urinary incontinence in females: Preoperative evaluation for a primary procedure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8088.html" rel="external">
          "Surgical management of stress urinary incontinence in females: Preoperative evaluation for a primary procedure", section on 'Office testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H415856870">
         <span class="h2">
          Consent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women are counseled regarding the alternative nonsurgical and surgical therapies as well as risks, benefits, complications, and success rates of pubovaginal slings. (See
         <a class="medical medical_review" href="/z/d/html/15076.html" rel="external">
          "Informed procedural consent", section on 'Informed decision-making'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20186384">
         <span class="h2">
          Antibiotic prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with the American College of Obstetricians and Gynecologists and the American Urological Association recommendation for antibiotic prophylaxis  (
         <a class="graphic graphic_table graphicRef87200" href="/z/d/graphic/87200.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">
          "Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Antimicrobial prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20186390">
         <span class="h2">
          Venous thromboembolism prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend sequential compression devices as a minimum intervention and consider additional pharmacologic prophylaxis in patients with multiple risk factors (see
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         ). Rectus fascial sling is typically classified as a "high-risk" procedure for developing venous thromboembolism (VTE) [
         <a href="#rid12">
          12
         </a>
         ]. A retrospective analysis of VTE in women undergoing urogynecologic surgery who were treated with sequential compression devices reported a VTE incidence of 0.3 percent [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H415856770">
         <span class="h1">
          TECHNIQUE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autologous pubovaginal slings are constructed from abdominal rectus fascia or fascia lata. Rectus fascia was used in the earliest reported slings as it was in the operative field, and it continues to be the best studied sling graft material. Fascia lata is a reasonable alternative if the rectus fascia is insufficient or there is a large pannus. Rectus fascia and fascia lata share the benefits of being autologous materials with low rates of graft-related complications and failures when compared with allografts, xenografts, and synthetic meshes [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
         The harvested fascia is placed transvaginally at the level of the proximal urethra, adjacent to the bladder neck. Permanent sutures are attached to the corners of the sling, passed retropubically, then secured superiorly above the rectus fascia [
         <a href="#rid16">
          16,17
         </a>
         ]. The technique varies somewhat based on the sling material (autologous fascia, allograft, xenograft, or synthetic); however, the most high-quality outcome data exist using rectus fascia as the sling material [
         <a href="#rid16">
          16
         </a>
         ]. Our technique for autologous rectus fascial sling is described in more detail below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anesthesia
         </strong>
         – Rectus fascial sling procedures are performed in the operating room under regional or general anesthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positioning
         </strong>
         – The patient is positioned in dorsal lithotomy position to allow for combined access to the lower abdomen and vagina. A bladder catheter is inserted and kept for the remainder of the case.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Harvesting fascia and preparing sling
         </strong>
         – A small 4 to 5 cm transverse suprapubic incision is made and a rectangular piece of rectus fascia (approximately 2 x 8 cm) harvested. The harvest site is closed in a tension-free fashion using a delayed absorbable suture. Permanent sutures are affixed to the four corners of the harvested rectus fascia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaginal dissection
         </strong>
         – A midline incision is made in the anterior vaginal wall at the level of the urethrovesical junction. The urethrovesical junction is easily identified by applying gentle downward traction on the bladder catheter so the balloon resides at the bladder neck, and thus identifies the urethrovesical junction. Using a combination of blunt and sharp dissection, the surgeon creates peri-urethral and retropubic tunnels bilaterally; the tunnels start in the vaginal dissection and extend into the retropubic space. Once the surgeon can feel the bottom of the pubic symphysis in the peri-urethral tunnel, she advances her finger into the retropubic space (aiming towards the ipsilateral shoulder), while gently swiping the bladder medially to prevent perforation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Passing sling
         </strong>
         – A long instrument (eg, uterine packing forceps or Stamey needle) is passed through the rectus fascia, behind the pubic bone, into the retropubic space and exits through the vaginal incision described in the paragraph above. The sling suture arms are grasped with the clamp and then passed from the vaginal to the abdominal fields. This is repeated on both sides, so that the sling lay under the urethrovesical junction or proximal urethra. Several fine absorbable sutures are placed to fix the sling to the periurethral tissues. Although surgeons have used bone anchors in the pubic symphysis as the superior sling attachment site, rectus fascia is preferred because bone anchors are associated with complications such as osteomyelitis pubis and do not improve the continence outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cystoscopy
         </strong>
         – Cystoscopy is performed with a 70-degree cystoscope to ensure the sling and dissection have not perforated the bladder and both ureters efflux briskly. The urothelium should also be assessed for any abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tensioning sling
         </strong>
         – The sling suture arms are then pulled up and tied above the rectus fascia, so the sling lays at the proximal urethra under no tension. A small curved clamp can be placed between the sling and the urethra; the clamp prevents overtightening the sling.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incision closure
         </strong>
         – The vaginal skin incisions using a running fine absorbable suture; the skin incision is closed in a subcuticular fashion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20186444">
         <span class="h1">
          OTHER SLING MATERIALS
         </span>
        </p>
        <p class="headingAnchor" id="H261417131">
         <span class="h2">
          Autologous slings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fascia lata and rectus fascia share the benefits of being autologous materials with low rates of graft-related complications and/or failures when compared with allografts, xenografts, and synthetic meshes [
         <a href="#rid14">
          14,18
         </a>
         ]. While no comparative data exist, most surgeons prefer rectus fascia to fascia lata because it is done through the same suprapubic incision that is used to secure the sling arms to the rectus fascia. Fascia lata harvesting requires patient repositioning during the surgery to allow access to the leg, and a leg incision. However, fascia lata is an alternative for patients with contraindications to harvesting rectus fascia (eg, prior low ventral hernia repair with mesh).
        </p>
        <p class="headingAnchor" id="H415857289">
         <span class="h2">
          Allograft slings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allograft
         <em>
         </em>
         slings (cadaveric fascia lata or lyophilized dura mater) have been used to decrease the morbidity associated with harvesting autologous grafts (see
         <a class="medical medical_review" href="/z/d/html/2879.html" rel="external">
          "Reconstructive materials used in surgery: Classification and host response", section on 'Allografts'
         </a>
         ). However, allograft pubovaginal slings are less effective when compared with autologous pubovaginal slings. In a 2011 meta-analysis of six trials, patient-reported improvement rates within one year of surgery favored autologous rectus fascia over other biological materials [
         <a href="#rid15">
          15
         </a>
         ]. In general, allografts are reserved for patients who are not candidates for mesh and who decline the use of autografts.
        </p>
        <p class="headingAnchor" id="H415857295">
         <span class="h2">
          Xenograft slings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Xenograft pubovaginal slings are generally not used secondary to high SUI recurrence rates [
         <a href="#rid19">
          19,20
         </a>
         ]. The rationale for xenograft use was to minimize morbidity associated with harvesting allografts and complications associated with mesh. (See
         <a class="medical medical_review" href="/z/d/html/2879.html" rel="external">
          "Reconstructive materials used in surgery: Classification and host response", section on 'Xenografts'
         </a>
         .)
        </p>
        <p>
         One multicenter trial randomized 201 women with urodynamically proven stress incontinence to receive either a porcine dermis xenograft pubovaginal sling, autologous fascial pubovaginal sling, or polypropylene mesh midurethral sling [
         <a href="#rid20">
          20
         </a>
         ]. At six months postoperatively, SUI improvement rates in the porcine dermis arm were significantly lower than autologous fascial and mesh slings (73 versus 95 versus 92 percent, respectively). Similarly, a case series using porcine dermis pubovaginal slings reported SUI success rates of 43 percent, with a mean time to recurrence of 10.4 months [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H415857301">
         <span class="h2">
          Synthetic slings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pubovaginal and midurethral slings are synthetic type I meshes constructed of polypropylene (see
         <a class="medical medical_review" href="/z/d/html/2879.html" rel="external">
          "Reconstructive materials used in surgery: Classification and host response", section on 'Synthetic materials'
         </a>
         ). The majority of incontinence slings are midurethral polypropylene slings. The use of other synthetic material for pubovaginal slings (polyethylene and expanded polytetrafluoroethylene) has been associated with urethral erosion rates of 8 and 12.5 percent, respectively [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H164574928">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Minor complications or adverse events after autologous fascia pubovaginal sling can range from 29 to 63 percent [
         <a href="#rid16">
          16,23
         </a>
         ], while serious adverse events in one randomized trial occurred in only 13 percent [
         <a href="#rid16">
          16
         </a>
         ]. Some of the more common complications are highlighted below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cystitis
         </strong>
         – Cystitis is the most common immediate adverse event after pubovaginal sling, with 48 percent of patients having a urinary tract infection during two years of follow-up [
         <a href="#rid16">
          16
         </a>
         ]. As positive urine cultures were not required in this study, the reported rate of urinary tract infection may be overestimated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urinary retention
         </strong>
         – One trial of 655 women randomized to pubovaginal sling or Burch procedure reported greater urinary retention rates for the pubovaginal sling patients than the Burch patients (66 percent versus 42 percent) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urge urinary incontinence
         </strong>
         – Rates of postoperative urinary urge incontinence range from 18 to 40 percent [
         <a href="#rid16">
          16,23,24
         </a>
         ]. In one study, women who had a pubovaginal sling compared with women who had Burch procedure were almost twice as likely to receive treatment for postoperative urge urinary incontinence six weeks after surgery [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Voiding dysfunction
         </strong>
         – Voiding dysfunction after pubovaginal sling ranges from 10 to 14 percent in the first six to eight weeks after surgery [
         <a href="#rid16">
          16,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cystotomy
         </strong>
         – Incidence of cystotomy at the time of rectus fascial sling ranges from 1 to 3 percent [
         <a href="#rid16">
          16,19
         </a>
         ]. Reported incidence of bladder perforation is lower with rectus fascial sling compared with retropubic midurethral sling [
         <a href="#rid25">
          25
         </a>
         ], possibly because of the more extensive dissection with suburethral rectus fascial sling.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H415856891">
         <span class="h1">
          POSTOPERATIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the risk of prolonged urinary retention and voiding dysfunction postoperatively, all women undergo a standardized voiding trial prior to discharge or removal of an indwelling catheter [
         <a href="#rid26">
          26
         </a>
         ]. A commonly used protocol includes retrograde filling the bladder with 300 mL of sterile
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or water through the patient’s catheter. The catheter should be immediately removed and the patient asked to void on the toilet with a collection device to measure the voided volume. If the patient voids at least 150 mL, the catheter does not need to be replaced. Women with elevated postvoid residual urine volumes (&gt;150 mL) should have some type of ongoing bladder drainage (intermittent self-catheterization, indwelling transurethral catheter, or suprapubic catheter) until urinary retention resolves (see
         <a class="medical medical_review" href="/z/d/html/6883.html" rel="external">
          "Acute urinary retention", section on 'Bladder decompression'
         </a>
         ). In women undergoing midurethral sling, no patient who met these criteria required additional catheterization [
         <a href="#rid27">
          27
         </a>
         ]; however, given the higher retention rates after pubovaginal slings, the false positive rate may be higher. Occasionally, if urinary retention persists, additional surgery may be necessary to loosen the sling. The timing for facial sling release varies by surgeon and ratio of voided to postvoid residual urine volumes over time. If the patient requires catheterization beyond four to six weeks, we recommend loosening of the sling to minimize risks of developing urinary urgency and urgency incontinence. Pelvic floor physical therapy with mobilization of the vaginal and abdominal incisions can hasten resumption of normal voiding in some women.
        </p>
        <p>
         Incisional pain is typically well controlled with oral anti-inflammatory agents and narcotics. Patients can expect pain resolution in the first few weeks after surgery. (See
         <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">
          "Approach to the management of acute pain in adults"
         </a>
         .)
        </p>
        <p>
         Patients are counseled to expect some vaginal spotting from the vaginal incision and refrain from placing anything in the vagina or having vaginal intercourse for four to six weeks while the incision heals. Few data exist to guide surgeons and patients regarding resumption of normal activities. Patient information regarding care after pelvic surgery can be found separately. (See
         <a class="medical medical_patient" href="/z/d/html/8393.html" rel="external">
          "Patient education: Care after gynecologic surgery (Beyond the Basics)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20186456">
         <span class="h1">
          CONTINENCE RATE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Efficacy of pubovaginal slings varies by comparator [
         <a href="#rid3">
          3,16,28
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2007 randomized trial comparing autologous fascial pubovaginal sling with Burch colposuspension, the overall continence rates were statistically higher with fascial sling (47 versus 38 percent) at 24-month follow-up [
         <a href="#rid16">
          16
         </a>
         ]. Similarly, treatment satisfaction rates at 24 months were statistically higher in the pubovaginal sling patients as compared with the Burch procedure patients (86 versus 76 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2014 meta-analysis of randomized trials, autologous fascial pubovaginal sling (pubovaginal type) compared with midurethral sling, subjective cure favored midurethral sling (odds ratio [OR] 0.40, 95% CI 0.18-0.85) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2020 meta-analysis that included 14 trials comparing continence outcomes for pubovaginal slings and midurethral slings, pubovaginal slings were probably not better and possibly less effective in the first one to five years after surgery (67 versus 74 percent, OR 0.67, 95% CI 0.44-1.02, n = 458). However, midurethral slings were associated with fewer perioperative complications (risk ratio 1.74, 95% CI 1.16-2.60) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1836804465">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/122263.html" rel="external">
          "Society guideline links: Incontinence surgery in women"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/109273.html" rel="external">
          "Society guideline links: Urinary incontinence in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/122885.html" rel="external">
          "Society guideline links: Gynecologic surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20187243">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – Pubovaginal slings are reserved for rare individuals in whom midurethral slings are contraindicated, were unsuccessful, or for those who decline a synthetic sling. Midurethral slings are preferred because of similar efficacy with decreased morbidity, urinary tract infection, and voiding dysfunction. (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Women undergoing pubovaginal slings should, at a minimum, report bothersome SUI symptoms, demonstrate signs of SUI, and have a normal postvoid residual urine volume and a negative urinalysis. (See
         <a class="local">
          'Preoperative evaluation and considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Office evaluation is adequate for women with predominant SUI symptoms planning to undergo a pubovaginal sling. If the urinalysis, cough stress test, and postvoid residual urine volume are consistent with uncomplicated SUI, then urodynamic testing is not necessary. (See
         <a class="local">
          'Preoperative evaluation and considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical materials
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Autologous fascia
         </strong>
         – Rectus fascia harvested from the patient (autologous graft) is the preferred non-mesh graft material because it has the highest success rate for treating SUI and minimizes the number of surgical sites. (See
         <a class="local">
          'Technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Allografts
         </strong>
         – Allografts are reserved for patients who are not candidates for mesh or autologous graft, but the continence failure rates are higher than for mesh and autologous graft. We do not use xenografts because of the high rate of SUI recurrence. (See
         <a class="local">
          'Other sling materials'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical procedure
         </strong>
         – Pubovaginal fascial slings are placed at the level of the proximal urethra or bladder neck. The superior attachment of the sling arms is to the rectus fascia. We do not use bone anchors because of higher risk of failure and complication. (See
         <a class="local">
          'Technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Common complications of pubovaginal slings include cystitis, urinary retention, and voiding dysfunction. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative voiding trial
         </strong>
         – All women should undergo a standardized voiding trial after placement of a pubovaginal sling. A common protocol includes retrograde filling the bladder with 300 mL of sterile
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or water through the patient’s catheter. The catheter should be immediately removed and the patient asked to void on the toilet with a collection device to measure the voided volume. If the patient voids at least 150 mL, the catheter does not need to be replaced. Women with elevated postvoid residual urine volumes (&gt;150 mL) should have some type of ongoing bladder drainage (intermittent self-catheterization, indwelling transurethral catheter, or suprapubic catheter) until urinary retention resolves. (See
         <a class="local">
          'Postoperative care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continence rates
         </strong>
         – Continence rates after pubovaginal slings vary by comparator but are generally acceptable with high patient satisfaction rates. (See
         <a class="local">
          'Continence rate'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Oliphant SS, Wang L, Bunker CH, Lowder JL. Trends in stress urinary incontinence inpatient procedures in the United States, 1979-2004. Am J Obstet Gynecol 2009; 200:521.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JM, Gandhi MP, Shah AD, et al. Trends in inpatient urinary incontinence surgery in the USA, 1998-2007. Int Urogynecol J 2011; 22:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schimpf MO, Rahn DD, Wheeler TL, et al. Sling surgery for stress urinary incontinence in women: a systematic review and metaanalysis. Am J Obstet Gynecol 2014; 211:71.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joint Report on Terminology for Surgical Procedures to Treat Stress Urinary Incontinence in Women. Female Pelvic Med Reconstr Surg 2020; 26:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FitzGerald MP, Gitelis S, Brubaker L. Pubic osteomyelitis and granuloma after bone anchor placement. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeLancey JO. Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis. Am J Obstet Gynecol 1994; 170:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milose JC, Sharp KM, He C, et al. Success of autologous pubovaginal sling after failed synthetic mid urethral sling. J Urol 2015; 193:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCoy O, Vaughan T, Nickles SW, et al. Outcomes of Autologous Fascia Pubovaginal Sling for Patients with Transvaginal Mesh Related Complications Requiring Mesh Removal. J Urol 2016; 196:484.
          </a>
         </li>
         <li class="breakAll">
          AUGS and SUFU Position Statement on Mesh Midurethral Slings for SUI www.augs.org/p/cm/ld/fid=599.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nager CW, Brubaker L, Litman HJ, et al. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med 2012; 366:1987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Urogynecologic Society and American College of Obstetricians and Gynecologists. Committee opinion: evaluation of uncomplicated stress urinary incontinence in women before surgical treatment. Female Pelvic Med Reconstr Surg 2014; 20:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Practice Bulletins--Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 84: Prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol 2007; 110:429. Reaffirmed 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon ER, Frick AC, Paraiso MF, Barber MD. Risk of deep venous thrombosis and pulmonary embolism in urogynecologic surgical patients. Am J Obstet Gynecol 2010; 203:510.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handa VL, Stone A. Erosion of a fascial sling into the urethra. Urology 1999; 54:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rehman H, Bezerra CC, Bruschini H, Cody JD. Traditional suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev 2011; :CD001754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albo ME, Richter HE, Brubaker L, et al. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med 2007; 356:2143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGuire EJ, Lytton B. Pubovaginal sling procedure for stress incontinence. 1978. J Urol 2002; 167:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webster TM, Gerridzen RG. Urethral erosion following autologous rectus fascial pubovaginal sling. Can J Urol 2003; 10:2068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broussard AP, Reddy TG, Frilot CF 2nd, et al. Long-term follow-up of porcine dermis pubovaginal slings. Int Urogynecol J 2013; 24:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerrero KL, Emery SJ, Wareham K, et al. A randomised controlled trial comparing TVT, Pelvicol and autologous fascial slings for the treatment of stress urinary incontinence in women. BJOG 2010; 117:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wohlrab KJ, Erekson EA, Myers DL. Postoperative erosions of the Mersilene suburethral sling mesh for antiincontinence surgery. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbalias G, Liatsikos E, Barbalias D. Use of slings made of indigenous and allogenic material (Goretex) in type III urinary incontinence and comparison between them. Eur Urol 1997; 31:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athanasopoulos A, Gyftopoulos K, McGuire EJ. Efficacy and preoperative prognostic factors of autologous fascia rectus sling for treatment of female stress urinary incontinence. Urology 2011; 78:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenton K, Richter H, Litman H, et al. Risk factors associated with urge incontinence after continence surgery. J Urol 2009; 182:2805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richter HE, Burgio KL, Brubaker L, et al. Continence pessary compared with behavioral therapy or combined therapy for stress incontinence: a randomized controlled trial. Obstet Gynecol 2010; 115:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton PA, Nager CW, Chai TC, et al. Risk factors for incomplete bladder emptying after midurethral sling. Urology 2013; 82:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAchran SE, Goldman HB. Contemporary length of stay and resource utilization when using a fast-track regimen for mid-urethral sling surgery. Urology 2009; 74:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraswat L, Rehman H, Omar MI, et al. Traditional suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev 2020; 1:CD001754.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14216 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19375571" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Trends in stress urinary incontinence inpatient procedures in the United States, 1979-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21975533" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trends in inpatient urinary incontinence surgery in the USA, 1998-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24487005" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Sling surgery for stress urinary incontinence in women: a systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32079836" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Joint Report on Terminology for Surgical Procedures to Treat Stress Urinary Incontinence in Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10543346" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pubic osteomyelitis and granuloma after bone anchor placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8203431" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25245488" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Success of autologous pubovaginal sling after failed synthetic mid urethral sling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26997314" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Outcomes of Autologous Fascia Pubovaginal Sling for Patients with Transvaginal Mesh Related Complications Requiring Mesh Removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26997314" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Outcomes of Autologous Fascia Pubovaginal Sling for Patients with Transvaginal Mesh Related Complications Requiring Mesh Removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22551104" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A randomized trial of urodynamic testing before stress-incontinence surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25181373" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Committee opinion: evaluation of uncomplicated stress urinary incontinence in women before surgical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17666620" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : ACOG Practice Bulletin No. 84: Prevention of deep vein thrombosis and pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20800214" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk of deep venous thrombosis and pulmonary embolism in urogynecologic surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10754153" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Erosion of a fascial sling into the urethra.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21249648" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Traditional suburethral sling operations for urinary incontinence in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17517855" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Burch colposuspension versus fascial sling to reduce urinary stress incontinence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11905885" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pubovaginal sling procedure for stress incontinence. 1978.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14704112" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Urethral erosion following autologous rectus fascial pubovaginal sling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22911448" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Long-term follow-up of porcine dermis pubovaginal slings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20939862" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A randomised controlled trial comparing TVT, Pelvicol and autologous fascial slings for the treatment of stress urinary incontinence in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19082911" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Postoperative erosions of the Mersilene suburethral sling mesh for antiincontinence surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9187896" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Use of slings made of indigenous and allogenic material (Goretex) in type III urinary incontinence and comparison between them.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22054371" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Efficacy and preoperative prognostic factors of autologous fascia rectus sling for treatment of female stress urinary incontinence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19837421" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risk factors associated with urge incontinence after continence surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20177294" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Continence pessary compared with behavioral therapy or combined therapy for stress incontinence: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24358480" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Risk factors for incomplete bladder emptying after midurethral sling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19592077" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Contemporary length of stay and resource utilization when using a fast-track regimen for mid-urethral sling surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31990055" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Traditional suburethral sling operations for urinary incontinence in women.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
